Single intravenous tranexamic acid dose to reduce blood loss in primary total knee replacement;Dosis única intravenosa de ácido tranexámico como medida de ahorro transfusional en prótesis total primaria de rodilla

Revista Espanola de Cirugia Ortopedica y Traumatologia

Volumn 60, Issue 2, 2016, Pages 106-112

  Sanz Reig, J ^a   Parra Ruiz, B ^a   Ferrandez Martinez J ^a   Martinez Lopez J F ^a  

^a Sant Joan d'Alacant   (Spain)

Author keywords

Bloodless surgery; Total knee replacement; Tranexamic acid

Indexed keywords

ANTIFIBRINOLYTIC AGENT; TRANEXAMIC ACID;

AGED; BLOOD AUTOTRANSFUSION; BLOOD LOSS, SURGICAL; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KNEE REPLACEMENT; MALE; MIDDLE AGED; PROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

AGED; ANTIFIBRINOLYTIC AGENTS; ARTHROPLASTY, REPLACEMENT, KNEE; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION, AUTOLOGOUS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TRANEXAMIC ACID; TREATMENT OUTCOME;

EID: 84958232490     PISSN: 18884415     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.recot.2015.11.004     Document Type: Article

References (29)

1. Hart A., Khalil J., Carli A., Huk O., Zukor D., Antoniou J. Blood transfusion in primary total hip and knee arthroplasty. Incidence, risk factors, and thirty-day complication rates. J Bone Joint Surg Am. 2014, 96:1945-1951.
2. Parvizi J., Chaudhry S., Rasouli M.R., Pulido L., Joshi A., Herman J.H., et al. Who needs autologous blood donation in joint replacement. J Knee Surg. 2011, 24:25-31.
3. Rasouli M.R., Gomes L.S., Parsley B., Barsoum W., Bezwada H., Cashman J., et al. Blood conservation. J Orthop Res. 2014, 32:81-89.
4. Leal-Noval S.R., Muñoz M., Asuero M., Contreras E., García-Erc J.C., Llau J.V., et al. Documento Sevilla de consenso sobre alternativas a la transfusión de sangre alogénica. Actualización del documento Sevilla. Rev Esp Anestesiol Reanim. 2013, 60. 263.e1-e25.
5. Carless P.A., Henry D.A., Moxey A.J., O'Connell D.L., Fergusson D.A. Cell salvage for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2010, CD001888.
6. Moreno Zurriaríana E., Echenique Elizondob M., Emparanza Knorrc J.I., Usabiaga Zarranza J. Cirugía sin sangre en las prótesis totales de rodilla. Rev Esp Cir Ortop Traumatol. 2008, 52:372-380.
7. Aguilera-Roig X., Jordán-Sales M., Natera-Cisneros L., Monllau-García J.C., Martínez-Zapata M.J. Ácido tranexámico en cirugía ortopédica. Rev Esp Cir Ortop Traumatol. 2014, 58:52-56.
8. O'Brien J.G., Battistini B., Zaharia F., Plante G.E., Sirois P. Effects of tranexamic acid and aprotinin, two antifibrinolytic drugs, on PAF-induced plasma extravasation in unanesthetized rats. Inflammation. 2000, 24:411-429.
9. Kim T.K., Chang C.B., Koh I.J. Practical issues for the use of tranexamic acid in total knee arthroplasty: a systematic review. Knee Surg Sports Traumatol Arthrosc. 2014, 22:1849-1858.
10. Poeran J., Rasul R., Suzuki S., Danninger T., Mazumdar M., Opperer M., et al. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. BMJ. 2014, 349:g4829.
11. Gandhi R., Evans H.M., Mahomed S.R., Mahomed N.N. Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis. BMC Res Notes 2013, 6:184.
12. Zarza-Pérez A., Hernández-Cortés P. Eficacia del uso del drenaje de autotransfusión en la cirugía primaria de prótesis de cadera y rodilla. Rev Esp Cir Ortop Traumatol. 2005, 49:187-192.
13. Moráis S., Ortega-Andreu M., Rodríguez-Merchán E.C., Padilla-Eguiluz N.G., Pérez-Chrzanowska H., Figueredo-Zalve R., et al. Blood transfusion after primary total knee arthroplasty can be significantly minimised through a multimodal blood-loss prevention approach. Int Orthop. 2014, 38:347-354.
14. Ortega-Andreu M., Pérez-Chrzanowska H., Figueredo R., Gómez-Barrena E. Blood loss control with two doses of tranexamic acid in a multimodal protocol for total knee arthroplasty. Open Orthop J. 2011, 5:44-48.
15. Gibon E., Courpied J.P., Hamadouche M. Total joint replacement and blood loss: what is the best equation?. Int Orthop 2013, 37:735-739.
16. López-Anglada E., Paz-Aparicio J., Bertrand D., Gosálbez J., Núñez-Batalla D., Paz-Jiménez J. Influencia de la aprotinina en el sangrado postoperatorio de la artroplastia total de rodilla. Rev Esp Cir Ortop Traumatol. 2005, 49:421-428.
17. Camarasa M.A., Olle G., Serra-Prat M., Martín A., Sánchez M., Ricós P., et al. Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial. Br J Anaesth 2006, 96:576-582.
18. Zufferey P., Merquiol F., Laporte S., Decousus H., Mismetti P., Auboyer C., et al. Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?. Anesthesiology 2006, 105:1034-1046.
19. Canillasa F., Gómez-Ramírez S., García-Erce J.A., Pavía-Molina J., Gómez-Luque A., Muñoz M. "Patient blood management" en cirugía ortopédica. Rev Esp Cir Ortop Traumatol. 2015, 59:137-149.
20. Ficha técnica Amchafibrin 500 mg solución inyectable [consultado 4 Jun 2014]. Disponible en: http://aemps.es/cima/pdfs/es/ft/53939/FT53939.pdf
21. Alshryda S., Sarda P., Sukeik M., Nargol A., Blenkinsopp J., Mason J.M. Tranexamic acid in total knee replacement: A systematic review and meta-analysis. J Bone Joint Surg Br. 2011, 93:1577-1585.
22. Kozek-Langenecker S.A., Afshari A., Albaladejo P., Alvarez Santullano C.A., de Robertis E., Filipescu D.C., et al. Management of severe perioperative bleeding. Guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013, 30:270-282.
23. Hourlier H., Fennema P. Single tranexamic acid dose to reduce perioperative morbidity in primary total hip replacement: a randomised clinical trial. Hip Int. 2014, 24:63-68.
24. Gomez-Barrena E., Ortega-Andreu M., Padilla-Eguiluz N., Pérez-Chrzanowska H., Figueredo-Zalve R. Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial. J Bone Joint Surg Am. 2014, 96:1937-1944.
25. Sa-ngasoongsong P., Wongsak S., Chanplakorn P., Woratanarat P., Wechmongkolgorn S., Wibulpolprasert B., et al. Efficacy of low-dose intra-articular tranexamic acid in total knee replacement; a prospective triple-blinded randomized controlled trial. BMC Musculoskeletal Disorders. 2013, 14:340.
26. Zhang H., Chen J., Chen F., Que W. The effect of tranexamic acid on blood loss and use of blood products in total knee arthroplasty: a meta-analysis. Knee Surg Sports Traumatol Arthrosc. 2012, 20:1742-1752.
27. Gillette B.P., DeSimone L.J., Trousdale R.T., Pagnano M.W., Sierra R.J. Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty. Clin Orthop Relat Res. 2013, 471:150-154.
28. Whiting D.R., Gillette B.P., Duncan C., Smith H., Pagnano M.W., Sierra R.J. Preliminary results suggest tranexamic acid is safe and effective in arthroplasty patients with severe comorbidities. Clin Orthop Relat Res. 2014, 472:66-72.
29. Rosencher N., Kerkkamp H.E., Macheras G., Munuera L.M., Menichella G., Barton D.M., et al. Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe. Transfusion. 2003, 43:459-469.